| Record ID | marc_loc_2016/BooksAll.2016.part22.utf8:216069230:1277 |
| Source | Library of Congress |
| Download Link | /show-records/marc_loc_2016/BooksAll.2016.part22.utf8:216069230:1277?format=raw |
LEADER: 01277nam a2200313 a 4500
001 93123698
003 DLC
005 19930708114654.0
008 930309s1992 dcua b f000 0 eng
010 $a 93123698
020 $a0160381290 :$c$2.75
040 $aDLC$cDLC
043 $an-us---
050 00 $aRC632.G36$bF43 1992
082 00 $a616.3/9$220
245 00 $aFederal and private roles in the development and provision of alglucerase therapy for Gaucher disease /$c[prepared by Alan M. Garber ... et al.].
260 $aWashington, DC :$bOffice of Technology Assessment :$bFor sale by the Supt. of Docs., U.S. G.P.O.,$c[1992]
300 $avii, 34 p. :$bill. ;$c26 cm.
490 1 $aBackground paper / Office of Technology Assessment
500 $a"October 1992"--Cover p. 4.
504 $aIncludes bibliographical references (p. 29-34).
500 $aS/N052-003-013096 (GPO).
500 $a"OTA-BP-H-104"--Cover p. 4.
650 0 $aGaucher's disease$xTreatment$zUnited States.
650 0 $aOrphan drugs$xUnited States.
650 0 $aPharmaceutical policy$xUnited States.
700 10 $aGarber, Alan M.
710 10 $aUnited States.$bCongress.$bOffice of Technology Assessment.
830 0 $aBackground paper (United States. Congress. Office of Technology Assessment).